FISH on a chip offers quicker, less costly cancer diagnosis

June 19, 2007

For the first time an important diagnostic test for cancer has been miniaturized and automated onto a microfluidic chip by a team of University of Alberta researchers in Edmonton, Canada.

This new technology opens up the possibility of better, faster cancer treatment and greater accessibility to the test, thanks to quicker and more cost-efficient diagnosis.

Chris Backhouse, professor of electrical engineering and cancer scientist Dr. Linda Pilarski have developed a microfluidic chip the size of a microscope slide that can perform fluorescent in situ hybridization (FISH) on a handheld diagnostic device.

FISH is an important and complex test that detects mutations in chromosomes for a number of different types of cancer. The test involves attaching coloured dyes to chromosomes as a way to visualize and count them as well as to detect cancer-promoting breaks and rejoinings of chromosomes. These abnormalities provide clinically valuable information about disease outcomes and response to therapy. This new system will allow FISH to be rapidly performed for a fraction of the cost of current analysis methods. Compared to conventional methods for FISH, which can take days to perform, the on-chip FISH test can be done in less than a day with a ten-fold higher rate of processing and a reduction in costs from hundreds to tens of dollars.

Because of the complexity and expense of current technology, FISH is infrequently used in clinical situations. FISH on a chip will allow widespread use of the tests because of its higher speed and lower costs. The rapid detection of chromosomal mutations will significantly increase a physician's ability to tailor treatment strategies to target individual cancers.

"The ability to design 'personalized' therapies means that patients will be able to receive more effective treatments sooner and avoid exposure to side effects from treatments that will not help them," Pilarski said.

"This is representative of how miniaturization can make our health care more accessible while creating new economic opportunities here in Alberta," Backhouse added.

"The work of Dr. Pilarski and her associates will have great impact, and quite quickly - on the diagnosis of patients with a broad spectrum of diseases," said Dr. Roderick McInnes, Scientific Director of the Canadian Institutes of Health Research Institute of Genetics. "Their FISH and chip technology should allow rapid and inexpensive diagnosis of important genetic changes that can underlie cancer and many developmental and neurological disorders. The type of product that these scientists have produced is a major example of the kind of innovation that Canada needs, innovation that grew out of the government's support of fundamental research in medicine and engineering."
-end-
The work is being published this month in IET Nanobiotechnology. It is also being presented at the 11th International Myeloma Workshop, a medical conference being held in Greece June 25-30.

Backhouse and Pilarski are part of the Alberta Cancer Diagnostic Consortium (ACDC), a multidisciplinary team at the University of Alberta and the Cross Cancer Institute that links engineering and medicine. The FISH and chip technology is one of several projects the group is developing and commercializing as automated, real-time tests for the detection and monitoring of cancer and other medical conditions. i-LOC Corp., a spin-off company supported by TEC Edmonton, the U of A's business incubator, was incorporated in November 2006 to commercialize the ACDC technology.

Funding for the research was provided by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council and Western Economic Diversification Canada.

For more information contact:

Dr. Linda Pilarski
Professor of Oncology
Faculty of Medicine and Dentistry
University of Alberta
780-432-8925
Linda.pilarsk@ualberta.ca

Dr. Chris Backhouse
Professor of Electrical and Computer Engineering
Faculty of Engineering
University of Alberta
780-492-2920
Christopher.backhouse@ualberta.ca

University of Alberta

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.